Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Articles|March 17, 2014
Overtreating DCIS
Author(s)Henry M. Kuerer, MD, PhD, FACS
Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses the overtreatment of DCIS.
Advertisement
Clinical Pearls
Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses the overtreatment of DCIS.
- 60,000-65,000 women are diagnosed with DCIS each year, though it is believed that many are overtreated
- It is difficult to determine which patients will progress to invasive breast cancer
- In order to get a better understanding of the disease process, researchers are testing the use of promising agents before surgery
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5